Df2156a    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
162類天疱瘡(後天性表皮水疱症を含む。)3

162. 類天疱瘡(後天性表皮水疱症を含む。) [臨床試験数:70,薬物数:117(DrugBank:46),標的遺伝子数:30,標的パスウェイ数:128
Searched query = "Pemphigoid", "Epidermolysis bullosa acquisita"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 70 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01571895
(ClinicalTrials.gov)
July 20114/4/2012Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous PemphigoidA Phase 2, Multicentre, Single Arm, Pilot Study to Assess the Efficacy and the Safety of 150 mg Twice a Day Oral DF2156A in Patients With Active Bullous Pemphigoid.Bullous PemphigoidDrug: DF2156ADompé Farmaceutici S.p.ANULLTerminated18 YearsN/ABoth4Phase 2Germany;Italy
2EUCTR2011-000756-42-IT
(EUCTR)
30/06/201120/03/2012pilot phase 2 clinical trial performed in some hospitals to evaluate the efficacy and the adverse events in a group of patients with active bullous pemphigoid that will receive DF2156A at the dose of 150 mg, oral route, twice a day.A phase 2, multicentre, single arm, pilot study to assess the efficacy and the safety of 150 mg twice a day oral DF2156A in patients with active bullous pemphigoid. - DF2156A in bullous pemphigoid active bullous pemphigoid
MedDRA version: 14.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: NA
Product Code: DF2156A
INN or Proposed INN: ladarixin
DOMPE' s.p.a.NULLNot RecruitingFemale: yes
Male: yes
12Phase 2Germany;Italy
3EUCTR2011-000756-42-DE
(EUCTR)
08/06/2011Pilot phase 2 clinical trial performed in some hospitals to evaluate the efficacy and the adverse events in a group of patients with active bullous pemphigoid that will receive DF2156A at the dose of 150 mg, oral route, twice a day.A phase 2, multicentre, single arm, pilot study to assess the efficacy and the safety of 150 mg twice a day oral DF2156A in patients with active bullous pemphigoid. - DF2156A in patients with active bullous pemphigoid active bullous pemphigoid
MedDRA version: 14.0;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: not applicable
Product Code: DF2156A
INN or Proposed INN: ladarixin
Dompé s.p.a.NULLNot RecruitingFemale: yes
Male: yes
12Phase 2Germany;Italy